Did you know that more than 1 in 3 individuals in the US are not up to date on colorectal cancer screening? ?? Early diagnosis of CRC can significantly improve treatment options and survival rates. Don't delay. Talk with your healthcare provider about getting screened today! Your health is a priority! ?? #ColorectalCancer #GetScreened #EarlyDetection #HealthAwareness #CancerPrevention
Geneoscopy
生物技术研究
St. Louis,MO 6,962 位关注者
Cancer Prevention | Diagnostics | Precision Medicine
关于我们
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense? test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
- 网站
-
https://geneoscopy.com
Geneoscopy的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- St. Louis,MO
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Life Sciences、Noninvasive Diagnostic Screening、Colorectal Cancer Screening、GI Health、GI Disease Companion Diagnostics、seRNA、RNA Biomarkers、Precision Medicine Partnerships和IBD
地点
-
主要
2220 Welsch Industrial Ct
US,MO,St. Louis,63146
Geneoscopy员工
动态
-
Colorectal cancer (CRC) screening is evolving, and experts like Uri Ladabaum, MD, MS, a member of the Stanford Cancer Institute and professor of medicine (gastroenterology & hepatology), emphasize the necessity for accessible and effective solutions Geneoscopy shares this vision. ColoSense harnesses the power of RNA biomarkers for the qualitative detection of colorectal cancer and advanced adenomas and is indicated for adults 45+ at average risk. Learn more about Dr. Ladabaum’s insights in Stanford Medicine: https://stan.md/4c0jNJf Learn more about ColoSense: https://bit.ly/40sqdNj #ColorectalCancer #Screening #EarlyDetection #AdvancedAdenomas #ColoSense #CancerPrevention
-
Did you know? People born in 1990 have double the risk of colon cancer compared to those born in 1950. Colorectal cancer is on the rise in young adults. Screening for colorectal cancer should begin at age 45 -- earlier for those who have a family history or symptoms. Talk to your provider, get screened and share this important information. #YoungAdultCRC #CRCawareness #Prevention #ScreeningSavesLives #ColorectalCancerAwarenessMonth
-
-
Feeling lucky this St. Patrick’s Day? ?? Don’t leave your health to chance. Colorectal cancer is highly treatable when caught early—make regular screenings part of your routine. Prioritize your well-being today and celebrate good health all year round! #StPatricksDay #ColorectalCancerAwareness #CRC #EarlyDetection #HealthIsWealth
-
We're #hiring a new Senior Manager, Medicaid Market Access in United States. Apply today or share this post with your network.
-
We're #hiring a new Customer Service Supervisor in United States. Apply today or share this post with your network.
-
Knowledge is power! ?? Think you know colorectal cancer? Test yourself. Then, discover a new way to screen for colorectal cancer with ColoSense, Geneoscopy's FDA-approved at-home screening test. ColoSense harnesses the power of RNA biomarkers to detect colorectal cancer and advanced adenomas. Learn more: https://bit.ly/40sqdNj #KnowledgeIsPower #ColorectalCancer #AtHomeScreening #RNABiomarkers #AdvancedAdenomas #StayInformed
-
Geneoscopy's CCO Matt Sargent and VP Jackie Moriarty joined Fight Colorectal Cancer's Anjee Davis and relentless advocates from across the country on Capitol Hill to unite our voices for change in the fight against colorectal cancer. When we all come together, we CAN make a difference. #ColorectalCancerAwarenessMonth #ScreeningSavesLives #UnitetoFightCRC
-
-
March is Colorectal Cancer Awareness Month! This month, Chief Medical and Science Officer, Erica Barnell, shines a light on the importance of early detection and innovative solutions in the fight against colorectal cancer. Discover how a site-less model and social media led to success during the pandemic in Geneoscopy's pivotal CRC-PREVENT clinical trial for ColoSense, the FDA-approved, RNA-based colorectal cancer screening test. Learn more about this impactful trial here in Clinical Leader: https://bit.ly/4iytmBe #ColorectalCancerAwarenessMonth #Geneoscopy #ColoSense #CancerResearch #EarlyDetection #HealthInnovation
-
-
Did you know that when detected early, the survival rate for colorectal cancer exceeds 90%? Getting screened can truly save lives! Talking with your healthcare provider about regular screenings and available options is crucial. If you're at average risk, screenings should start at age 45 or earlier if you have a family history or other risk factors. Don’t wait for symptoms—take proactive measures for your health and your loved ones. Together, we can work towards ending colorectal cancer! #ColorectalCancerAwareness #GetScreened #CancerSurvivor #HealthMatters
-